On July 18, 2023 Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Cancer Research Horizons, the innovation engine at the core of one of the world’s largest private funders of cancer research, Cancer Research UK (CRUK), reported an agreement under which Cancer Research Horizons will license the entire Twist Biopharma Solutions Library of Libraries (Press release, Twist Bioscience, JUL 18, 2023, View Source [SID1234633305]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Teaming up with Cancer Research Horizons to support exploratory drug discovery efforts, validating and de-risking biological targets has the potential to be groundbreaking for patients," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "Cancer Research Horizons acts as a conduit between academia and industry, with our collaboration enabling early-stage antibody identification through access to our ‘Library of Libraries.’ With two mission-driven organizations aligning behind innovative technology solutions to improve health to make the world a better place, the opportunity to identify new biotherapeutics offers tremendous hope to those who need it most."
"We’re delighted to partner with Twist Bioscience, an exciting technology platform company who will enhance our antibody discovery capabilities with their highly diverse phage display libraries," said Hamish Ryder, CEO of Therapeutic Innovation at Cancer Research Horizons. "We look forward to using this technology to accelerate the delivery of high-quality therapeutics and diagnostics to cancer patients, in collaboration with our academic and industrial partners."
Under the terms of the agreement, Cancer Research Horizons will license Twist’s Library of Libraries, an expansive collection of synthesized antibody libraries designed based on naturally occurring sequences that harness innovative structural and developability features to cover a wide range of antibody drug targets, for a period of five years. Twist will receive a library access fee and will be eligible to receive annual maintenance fees as well as a share of revenue from any assets sold or transferred.